Recurrent Ovarian Cancer Clinical Trials

10 recruiting

Recurrent Ovarian Cancer Trials at a Glance

11 actively recruiting trials for recurrent ovarian cancer are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Leuven, Madrid, and Guangzhou. Lead sponsors running recurrent ovarian cancer studies include Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Akeso, and AbbVie.

Browse recurrent ovarian cancer trials by phase

Treatments under study

About Recurrent Ovarian Cancer Clinical Trials

Looking for clinical trials for Recurrent Ovarian Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Ovarian Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Ovarian Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recurrent Ovarian CancerFolate Receptor-Alpha Positive
AbbVie100 enrolled40 locationsNCT06365853
Recruiting
Not Applicable

Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study

Recurrent Ovarian CancerPlatinum Resistance
The First Hospital of Jilin University40 enrolled1 locationNCT07495384
Recruiting
Phase 1Phase 2

Combination Therapy for Recurrent Ovarian Cancer

Recurrent Ovarian Cancer
Sham Sunder Kakar72 enrolled1 locationNCT05610735
Recruiting
Phase 2

QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

Treatment of Recurrent Ovarian Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University40 enrolled1 locationNCT07286240
Recruiting
Phase 1Phase 2

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Endometrial CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer+2 more
Regeneron Pharmaceuticals890 enrolled51 locationsNCT03564340
Recruiting
Phase 1

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

Advanced Breast CancerAdvanced Prostate CancerTNBC+3 more
Jiangsu Hansoh Pharmaceutical Co., Ltd.157 enrolled1 locationNCT06769425
Recruiting
Phase 1

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Recurrent Ovarian Cancer
Lan Coffman30 enrolled1 locationNCT05942300
Recruiting
Phase 2

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Recurrent Ovarian Cancer
Akeso172 enrolled1 locationNCT06560112
Recruiting
Phase 1

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Advanced Solid TumorPlatinum-resistant Recurrent Ovarian Cancer
Ascentage Pharma Group Inc.50 enrolled1 locationNCT06687070
Recruiting
Phase 2

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Platinum-resistant Recurrent Ovarian Cancer
Shanghai Jiaolian Drug Research and Development Co., Ltd90 enrolled17 locationsNCT06434610
Recruiting
Phase 2Phase 3

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

Recurrent Ovarian CancerSignal Transduction Pathway DeregulationTherapy-Associated Cancer
Gynaecologisch Oncologisch Centrum Zuid148 enrolled6 locationsNCT03458221